Glyconanoparticle Safety Pharmacology Service
Overview of Glyconanoparticle Safety Pharmacology
In the field of rapid development of biomedicine, glyconanoparticle, as a new type of functional biological nanomaterial, is showing its huge potential in drug transmission, imaging, and diagnosis. However, the introduction of any new drug or treatment method must be strictly evaluated. Therefore, CD BioGlyco provides glyconanoparticle safety pharmacology services to comprehensively evaluate the pharmacological safety and potential risks of glyconanoparticles.
Our glyconanoparticle safety pharmacology service is based on our advanced GlycoNano™ Platform, which integrates all-around services such as glyconanoparticle synthesis, representation, application, and security evaluation. As an important part of the platform, Glyconanoparticle Preclinical Study Services cover comprehensive clinical studies including glyconanoparticle safety pharmacology. Glyconanoparticle safety pharmacology services not only cover acute and chronic toxic research, but also include special research such as genetic toxicity, cardiac toxicity, neurotoxicity, and reproductive toxicity, which provides a solid security guarantee for glyconanoparticle pre-clinical study.
Discover the Future of Safety with Our Top-tier Glyconanoparticle Pharmacology Service
Glyconanoparticle Acute Toxicity Study Service
Our acute toxicity study service is designed to assess the immediate health risks posed by glyconanoparticles. We utilize state-of-the-art In Vivo and In Vitro Models to evaluate the acute response following exposure to these particles. Our methodology involves precisely measuring the lethal dose (LD50) and observing clinical signs, including behavioral changes and physiological reactions, over a short duration.

- Animal model selection: Mice or rats are commonly used as model organisms. According to the intended application of glyconanoparticles (such as intravenous injection and oral administration), the appropriate route of administration is selected.
- Observation indicators: In addition to conventional weight changes, behavioral abnormalities, and mortality, biomarker analysis (such as inflammatory factors and oxidative stress indicators) is also introduced to more sensitively capture toxic reactions.
- Customization: According to client needs, histopathological examinations at specific time points can be added, or detailed evaluations of specific organs (such as lungs and spleen) can be added.
Glyconanoparticle Chronic Toxicity Study Service
Chronic toxicity studies are vital for understanding the long-term implications of glyconanoparticle exposure. Our approach involves prolonged exposure assessments and regular monitoring of subjects over extended periods. Utilizing comprehensive biochemical, hematological, and histopathological analyses, we identify potential adverse effects that may manifest over time.

- Long-term dosing regimen: Design a multi-dose, multi-time point dosing regimen to simulate long-term exposure scenarios and evaluate cumulative toxic effects.
- Comprehensive evaluation system: In addition to conventional indicators, add multi-dimensional tests such as hematology, biochemistry, immunology, and molecular biology to build a comprehensive toxicity evaluation system.
- Histopathology and molecular biology: Perform detailed histopathological examinations of key organs, combined with gene expression analysis and proteomics research to reveal potential molecular mechanisms.
- Customization: Based on the characteristics of glyconanoparticles, functional tests of specific organs (such as lung function tests and renal function tests) can be added.
Glyconanoparticle Genotoxicity Study Service
We meticulously analyze the potential of glyconanoparticles to cause genetic mutations. We employ a battery of tests, including the Ames test, chromosomal aberration assay, and the micronucleus test to detect DNA damage and chromosomal instability. Our advanced methodologies ensure that genotoxic risks are minimized and offer a robust framework for assessing the genetic safety of nanoparticles.
- Genetic testing methods: Classical genetic methods such as Ames test, mammalian cell gene mutation test, and chromosome aberration test are used in combination with high-throughput sequencing technology to detect DNA damage and gene mutation.
- Cell culture and animal models: In vitro genetic toxicity tests are performed using human or mouse cell lines, and animal models are established for in vivo genetic toxicity assessment.
- Customization: According to the characteristics of glyconanoparticles, specific genetic toxicity endpoints can be added (such as DNA repair ability test and epigenetic change detection).
Glyconanoparticle Cardiotoxicity Study Service
Cardiotoxicity is a critical concern in safety pharmacology, and our dedicated service employs cutting-edge in vitro cardiomyocyte models and in vivo assessments. Tailor-made protocols evaluate specific types of nanoparticles across various cardiovascular conditions, ensuring precise and reliable data.
- Cardiac function assessment: Combined with hemodynamic analysis, monitor cardiac electrophysiological, and structural changes to comprehensively evaluate cardiac function.
- Cardiac cell research: Use primary cardiomyocytes or cardiomyocyte cell lines to conduct in vitro toxicity tests to observe cell survival rate, morphological changes, and calcium ion flow.
- Molecular mechanism exploration: Through gene expression analysis and protein interaction research, the molecular mechanism of glyconanoparticles on cardiac toxicity is revealed.
- Customization: Detailed analysis of cardiac electrophysiology can be added according to client needs.
Glyconanoparticle Neurotoxicity Study Service
The neurotoxicity study service focuses on identifying adverse effects on the nervous system. Utilizing neuronal cell cultures, animal models, and advanced imaging techniques, we examine the impact of glyconanoparticles on neurophysiology and neurobehavioral functions. Tests are customized to include a range of neurological assays and biomarkers, allowing comprehensive assessment and mitigation of neurotoxic risks.
- Neurobehavioral testing: The tests include open field test and water maze test to evaluate the cognitive function, motor ability, and emotional changes of animals.
- Neuroimaging: Magnetic resonance imaging (MRI), positron emission tomography (PET), and other technologies are used to observe changes in brain structure and function.
- Neural cell research: In vitro toxicity tests are performed using neurons or glial cells to observe cell proliferation, differentiation, and synapse formation.
- Customization: According to the characteristics of glyconanoparticles, specific neurotransmitter detection, and neural pathway activity analysis can be added.
Glyconanoparticle Reproductive Toxicity Study Service
Our reproductive toxicity study investigates the effects of glyconanoparticles on reproductive health and development. We incorporate multi-generational studies to observe impacts on fertility, embryonic development, and offspring viability. By offering customizable study designs, we address different exposure scenarios and reproductive endpoints, ensuring robust safety evaluations for reproductive health.
- Reproductive capacity assessment: Evaluate the effects of glyconanoparticles on male and female reproductive capacity through mating tests and fertility tests.
- Embryonic development research: Use in vitro fertilization, embryo culture, and other technologies to observe the effects of glyconanoparticles on embryonic development.
- Offspring health monitoring: Perform growth and development, behavioral tests, and reproductive capacity assessment on offspring to observe the cross-generational effects of glyconanoparticles.
- Customization: According to client needs, functional tests of specific reproductive organs (such as sex hormone level detection and sperm quality analysis) can be added.
We also offer a glyconanoparticle immunotoxicity study service that encompasses technical intricacies and customized solutions. Our immune system assessment utilizes flow cytometry, immunohistochemistry, and other techniques to evaluate the impact of glyconanoparticles on the number, function, and immune response of immune cells. We conduct cytokine and antibody detection by measuring changes in the levels of immune molecules such as cytokines and antibodies in serum, revealing the activation or suppression status of the immune system. Furthermore, we employ animal models with immune deficiencies or under specific immune stimulation conditions to delve deeper into the immunotoxicity of glyconanoparticles. Customization is available, allowing for detailed analysis of specific immune cell subsets (such as T cells, B cells, and NK cells) according to client requirements.
Applications of Glyconanoparticle Safety Pharmacology
- Glyconanoparticle safety pharmacology can be used to guide the design of safe and effective dosing regimens for glyconanoparticle-based therapeutics.
- Glyconanoparticle safety pharmacology can be used to identify potential adverse drug reactions associated with glyconanoparticle administration in vivo.
- Glyconanoparticle safety pharmacology can be used to evaluate the impact of glyconanoparticles on various organ systems and physiological functions in animals.
Advantages
- We offer comprehensive assessments that ensure the safety and efficacy of our glyconanoparticle-based products.
- Our services leverage cutting-edge technology and rigorous scientific methodologies, enabling us to provide precise and reliable data on the toxicity and safety profile of glyconanoparticles.
- Our services offer a tailored approach to meet the specific needs of our clients, providing customized experimental designs and comprehensive reporting.
Publication
Published: 2020
Journal: Frontiers in Oncology
IF: 3.64
Results: The article highlights the safety pharmacology aspects of glycosylated nanoparticles used in cancer-targeted drug delivery. These nanoparticles are designed to improve drug specificity and reduce toxicity by exploiting cancer cells' unique glycan patterns and lectin interactions. Glycosylated nanoparticles enhance the therapeutic index by ensuring better biocompatibility and minimizing non-specific interactions. They achieve this through their modified surfaces that improve pharmacokinetic profiles, resulting in lower toxicity compared to non-glycosylated counterparts. Additionally, the review addresses the challenges of maintaining stability, ensuring biocompatibility, and refining drug delivery efficacy in the development of these nanosystems.
Fig.1 Comparison of viability between MDA-MB-231 and HaCaT cell lines. (Torres-Pérez, et al., 2020)
Our Services
Glyconanoparticle Development Service
We specialize in glyconanoparticle development services, encompassing Carbohydrate-based Nanoparticle Production, Quantum Dot (QD) Glyconanoparticle Production, and Liposome Glyconanoparticle Production. This service is seamlessly integrated with our glyconanoparticle safety pharmacology Service, ensuring that every stage of your glyconanoparticle's journey is handled with precision and expertise.

Frequently Asked Questions
- What is glyconanoparticle safety pharmacology, and why is it important for my product development?
Glyconanoparticle safety pharmacology is a specialized service that assesses the potential toxicity and safety profile of glyconanoparticles, which are nanoparticles modified with sugar molecules. This service is critical to your product development as it can improve the safety of the glyconanoparticle-based therapeutics you develop. By evaluating the impact of these particles on various organ systems and physiological functions, we identify potential adverse drug reactions and guide the design of safe and effective dosing regimens. - What kind of tests and procedures are involved in your glyconanoparticle safety pharmacology service?
Our glyconanoparticle safety pharmacology service includes a range of tests and procedures tailored to the specific needs of your product. These may include in vitro toxicity assessments, animal studies to evaluate in vivo toxicity and pharmacodynamics, and pharmacokinetic studies to understand how the glyconanoparticles are absorbed, distributed, metabolized, and excreted. We also conduct comprehensive reporting and analysis to provide you with actionable insights and support your regulatory submissions.
At CD BioGlyco, our glyconanoparticle safety pharmacology service is a comprehensive and rigorous assessment of the safety and efficacy of glyconanoparticle-based therapeutics, leveraging cutting-edge technology and ethical research practices to ensure the highest standards of accuracy and reliability. We welcome clients to contact us for more information and to discuss their specific needs and goals.
Reference
- Torres-Pérez, S.A.; et al. Glyconanoparticles for cancer-targeted drug delivery. Frontiers in Oncology. 2020, 10: 605037.
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform





